Kinfo
Gri Bio Inc. logo

Gri Bio Inc.

GRINASDAQHealthcare·US · USD
$1.85
+0.03 (+1.65%)
Live · 2026-06-29

Price

Key statistics

Valuation
Market cap3.22M USD
Enterprise value-7.77M USD
Trailing P/E0.05
Forward P/E-0.72
PEG ratio-0.00
Price / sales0.00
Price / book0.27
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-88.82%
Return on equity-185.67%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-10.93M USD
Net income-10.91M USD
Diluted EPS$38.89
Rev. growth (YoY)0.00%
Balance sheet
Total cash11.05M USD
Total debt58.00K USD
Debt / equity0.55
Current ratio14.21
Book value / share$6.65
Cash flow (TTM)
Operating cash flow-12.13M USD
Levered free cash flow-7.80M USD
Shares & price
Shares outstanding1.58M
Float1.77M
Held by institutions2.80%
Beta-0.66
50-day MA$2.20
200-day MA$19.64
52-week high$80.36
52-week low$1.72
Dividends
Forward rate
$2.04
Yield
110.49%
Payout ratio
0.00%
Frequency
Quarterly
Recent payments
  • 2019-12-19$23,715.51
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-3.74-1.61+56.95%2026-01-30-29.26-116.61−298.53%2025-11-14-31.08-35.84−15.32%2025-08-14-36.68-36.68+0.00%2025-05-15-105.98-162.40−53.24%
About Gri Bio Inc.

Gri Bio Inc. is a biotechnology company dedicated to the development of innovative therapies, particularly focusing on immunology and inflammatory diseases. The primary function of the company is to research and create novel treatments that address unmet medical needs, leveraging cutting-edge scientific discoveries to advance human health. Their work predominantly impacts the healthcare and pharmaceutical sectors, with a significant emphasis on improving patient outcomes in challenging disease areas. Gri Bio Inc. plays a crucial role in the biotechnology market, contributing to the expansive growth and diversification of therapeutic options available to clinicians. By prioritizing transparency, collaboration, and rigorous scientific evaluation, the company aims to foster substantial progress within the biotech field, offering valuable advancements in medicine to stakeholders, including patients, healthcare providers, and the broader scientific community. Gri Bio Inc.'s commitment to excellence and pioneering research propels its significance and potential influence in the financial markets by addressing critical health challenges through breakthrough therapies.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. W. Marc Hertz Ph.D.
Employees
3
Headquarters
La Jolla, CA, United States

Frequently asked questions about Gri Bio Inc.